Canadian-managed healthcare fund says while the dual listing could have increased earnings by as much as 15%, ‘concerns’ had been raised.
Company chair says the capital raise would stave off a ‘significant restructuring’ after losing test coverage in its core US market.
Fee compression, capital markets headwinds and a sluggish outlook for its wealth platform all weighing on potential, analysts say.
The company’s share price is in the doldrums, but analysts see new hope in the arrival of Jayne Hrdlicka.
The listed investment company considers ‘strategic options’.
Rakon’s former boss has refused to support the appointment of three independent directors to the company’s board after he was overlooked for the role as chair.
However, Briscoe boss Rod Duke says forecasting is ‘so bloody hard to put your finger on...’
Hrdlicka was due to start at Endeavour Group in January 2026, but is now believed to be working part-time as incoming chief executive.
Listed tourism and campervan operator's board says the company is worth 'well north of $3.00 per share'.
Former interim CEO John Journee has been appointed as the retailer’s next chair, replacing Joan Withers, who says the board has been through ‘crucible of pain’.